Current drugs for pancreatic cancer lose effectiveness within months because the tumor becomes resistant. Now, a group from Spain’s National Cancer Research Centre (CNIO) has been able to avoid the development of resistance in animal models with a combined triple therapy. Mariano Barbacid, head of the Experimental Oncology Group at the CNIO, has designed a therapy that successfully eliminates pancreatic tumors in mice completely and durably, with no significant side effects.
This article was originally published on MedicalXpress.com
